To the Editor,
I wish to congratulate Underwood and colleagues for their review article [1] in which they presented a meta-analysis related to cognitive sequelae of endocrine therapy in women treated for breast cancer. They reported that verbal learning/memory was the only domain where endocrine therapy (ET) patients performed worse than both non-cancer and breast cancer (BC) controls. As far as I understand from Methods section, ET patients received only endocrine treatment. However, detailed information regarding whether patients received chemotherapy or not and if received how long and which schedules they received chemotherapy in BC control arm were not described. These factors might also affect cognitive sequelae of patients in BC control arm and should be taken into consideration when compared with ET patients [2].
References
Underwood EA, Rochon PA, Moineddin R, Lee PE, Wu W, Pritchard KI, Tierney MC (2017) Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis. Breast Cancer Res Treat. https://doi.org/10.1007/s10549-017-4627-4
Cerulla N, Arcusa À, Navarro JB, Garolera M, Enero C, Chico G, Fernández-Morales L (2017) Role of taxanes in chemotherapy-related cognitive impairment: a prospective longitudinal study. Breast Cancer Res Treat 164(1):179–187. https://doi.org/10.1007/s10549-017-4240-6
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
I have no conflict of interest to declare.
Rights and permissions
About this article
Cite this article
Altundag, K. Detailed information about chemotherapy in breast control arm might affect cognitive sequelae compared with endocrine therapy patients. Breast Cancer Res Treat 169, 203 (2018). https://doi.org/10.1007/s10549-018-4672-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-018-4672-7